

Question 1

Afatinib	<5
Alectinib	<5
Amivantamab	0
Atezolizumab monotherapy	<5
Atezolizumab with chemotherapy	<5
Brigatinib	0
Ceritinib	0
Crizotinib	0
Dacomitinib	0
Dabrafenib with Trametinib	0
Durvalumab	<5
Erlotinib	0
Gefitinib	<5
Lorlatinib	0
Mobocertinib	0
Nintedanib with Docetaxel	5
Nivolumab	<5
Osimertinib	12
Pembrolizumab monotherapy	32
Pembrolizumab with chemotherapy	34
Pemetrexed with Carboplatin/Cisplatin	5
Pralsetinib	0
Selpercatinib	0
Sotorasib	<5
Tepotinib	0
Vinorelbine with Carboplatin/Cisplatin	13
Any other active systemic anti-cancer therapy (SACT)	10
Palliative care only	Data is not available from

Question 2

Atezolizumab monotherapy	<5
Atezolizumab with chemotherapy	<5
Durvalumab	<5
Nivolumab	<5
Osimertinib	12
Pembrolizumab (Keytruda) Mono	32
Pembrolizumab (Keytruda) with Chemotherapy	34
Tepotinib	0
Other active systemic anti-cancer therapy (SACT)	40
Palliative care only	0